1. Can you please briefly summarize the paper?

Our study addresses the growing problem of diarrheal infections caused by multi-drug resistant Escherichia coli, particularly enterotoxigenic E. coli (ETEC). We introduce a dual-action therapeutic strategy combining bacteriophage therapy with bentonite, a natural clay mineral. While the phage EC.W2-6 efficiently eliminates bacterial populations, phage therapy in the gastrointestinal tract faces challenges such as acidic inactivation and the inflammatory release of toxins—specifically lipopolysaccharides (LPS) and outer membrane vesicles (OMVs)—during bacterial lysis.
Bentonite serves as a strong adsorbent, binding these toxins and preventing inflammatory damage. This combination therapy ensures effective pathogen removal while stabilizing the gut microbiota and promoting recovery from dysbiosis. The therapeutic efficacy was validated in a murine diarrheal model, where the treatment showed complete protection and restored gut microbiota diversity to levels resembling healthy controls. Our results suggest that integrating bacteriophage therapy with bentonite is a promising approach for treating antibiotic-resistant enteric infections by offering simultaneous pathogen removal and toxin neutralization.

Schematic overview of the dual-action therapeutic strategy

2. Can you please tell us the main difficulties you had in the laboratory work and how you overcame them?

The primary challenge was optimizing the bentonite-phage ratio to ensure high-capacity toxin adsorption without compromising phage stability or infectivity. While bentonite is an effective adsorbent for LPS and OMVs, its high surface charge can interfere with phage-host recognition and cause significant sedimentation at higher concentrations. This aggregation made it impossible to accurately quantify particles via Nanoparticle Tracking Analysis (NTA).

To overcome this, we conducted a systematic evaluation using zeta potential measurements. Through iterative experimentation, we mapped the physicochemical landscape of the interaction to identify the 'threshold' concentration where toxin neutralization was maximized while maintaining the phage's lytic efficiency. By optimizing this balance through in vivo dose-escalation studies, we transitioned from a problematic suspension to a stable, synergistic therapeutic platform that functioned effectively within the complex environment of the gastrointestinal tract.

3. Please introduce your laboratory, university or organization to bio-researchers in Korea.

This research was conducted in Dr. Shukho Kim’s Laboratory at Kyungpook National University (KNU). Our lab specializes in translational strategies against antimicrobial resistance, specifically the engineering of bacteriophages and endolysins to neutralize multi-drug resistant (MDR) pathogens. We operate at the intersection of medical microbiology and veterinary science, providing a unique environment for studying enteric diseases like ETEC from a One Health perspective.
A core focus of our facility is the interplay between therapeutic interventions and gut microbiome stability. Rather than simply killing pathogens, we investigate how to prevent post-lysis inflammation and dysbiosis. The strength of the KNU environment lies in this interdisciplinary convergence, which allows us to integrate material science—such as nanoclay-based toxin adsorption—with biological phage therapy. Our objective is to move beyond traditional antibiotic models by developing synergistic, ecologically stable treatments with direct applications in both clinical and veterinary medicine.

4. Please tell us your experiences and your thoughts related to research activities abroad.

My tenure at Kyungpook National University (KNU) has been a period of intense technical training, allowing me to evolve into a multidisciplinary researcher working at the intersection of bacteriophage biology and materials science. Being part of Korea’s highly structured, technology-driven research setting has shaped how I approach antimicrobial development, particularly in designing integrated, data-driven therapeutic strategies.
Beyond the laboratory bench, immersing myself in Korea’s fast-paced research culture has been a valuable lesson in methodological discipline. I came to understand that the emphasis on speed reflects a deeper commitment to precision, organization, and iterative refinement. During my PhD, adopting this approach helped me streamline my workflows and significantly improved my ability to manage complex research timelines.

5. Can you provide some advice for younger scientists who have plans to study abroad?

Thriving in a global research environment depends on a strategic shift from a 'learner' mindset to a 'problem-solver' mindset. My primary advice is to prioritize technical and computational readiness over theoretical perfection; mastering core analytical pipelines and data-processing frameworks before arriving allows a researcher to contribute to high-impact projects from day one.
Alongside technical proficiency, successful research depends on proactive integration into the host institution. Rather than working in isolation, younger scientists should actively identify “technical bridges” where their core expertise can align with the institution’s strengths, such as advanced materials science or high-throughput engineering platforms. By focusing these interdisciplinary connections and maintaining a proactive approach to both technical and logistical challenges, researchers can transform their time abroad into a strong foundation for a globally competitive research career.

6. Future plan?

My immediate goal is to complete my doctoral research, which focuses on the intersection of biological therapeutics and materials science. I aim to develop a robust platform for precision antimicrobials that target multidrug-resistant (MDR) pathogens while preserving host microbiome integrity.
In the long term, I hope to lead a research group that connects synthetic biology and materials science to engineer integrated therapeutic strategies combining biological lysis with nanomaterial-based detoxification. I also aim to establish myself as an independent investigator who fosters transnational collaborations between Korea and the global research community, contributing to innovative and ecologically stable alternatives to conventional antibiotics.

7. Do you have anything else that you would like to tell Korean scientists and students?

I am grateful for the opportunity to share my research through this platform. My ongoing PhD journey at KNU continues to show that meaningful scientific progress emerges from combining methodological discipline with interdisciplinary curiosity. The Korean research environment, which balances precision, speed, and strong collaboration, has provided an ideal setting for this growth.
I have found that the most impactful breakthroughs occur when the gaps between different fields, such as microbiology and material science, are bridged to solve complex problems. By maintaining an open approach to international cooperation and focusing on the technical integration of diverse fields, we can effectively address global threats like antimicrobial resistance. I hope we all continue to advance as researchers and contribute to the development of the next generation of biotherapeutics through dedicated and innovative research.